|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.01.26 - 07:03
|
IBA selected by MD Anderson Cancer Center to supply three Proteus®ONE systems (GlobeNewswire EN)
|
|
|
Louvain-La-Neuve, Belgium, January 19, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announced that it has signed a contract with the University of Texas MD Anderson Cancer Center, ranked #1 in cancer care by U.S. News & World Report, to re-equip and modernize its existing Proton Therapy Center in Houston with three state-of-the-art Proteus®ONE1 systems....
|
|
|
|
|
|
|
15.01.26 - 18:03
|
KBC Group: KBC completes the acquisition of 365.bank, strengthening its position in Slovakia (GlobeNewswire EN)
|
|
|
KBC Group today announces the successful completion of its acquisition of a 98.45% stake in 365.bank from J&T Finance Group. The deal originally announced on 15 May 2025, received approval from all relevant authorities and has now officially closed, enabling KBC to combine 365.bank with its Slovak operations anchored by ČSOB. The completion marks a significant milestone in KBC's long‑term growth strategy in Slovakia - a core market for the group - and reinforces its ambition to remain a leading financial player in Central and Eastern Europe.The total consideration paid for the 98.45% stake in 365.bank is EUR 708 million, reflecting closing adjustments. The acquisition will have a limited impact on KBC's capital position (approximately -50 basis points on KBC's unfloored fully loaded CET-1 ratio) which remains very solid keeping KBC's CET1 ratio well above regulatory minimum capital requirements....
|
|
|
|
|
|
|
10.01.26 - 17:36
|
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases (Business Wire)
|
|
|
Financing round led by RA Capital Management and Forge Life Science Partners, with contributions from new and existing investors
Proceeds to advance frevecitinib, an inhaled pan-JAK inhibitor with the potential to treat the broad severe asthma population, through Phase 2 studiesBOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel and differentiated inhaled therapeutic candidate to treat serious respiratory diseases, today announced the closing of a $103 million Series B financing. New investors RA Capital Management and Forge Life Science Partners led the financing, with participation from new investors EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital and existing investors, Atlas Venture, 5AM Ventures and Gimv.
“Since day one, our goal has been to develop a best-in-class therapeutic for the treatment of severe inflammatory respiratory disease. Critically, and unlike the majorit...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
